Patent · US Active

Method for the selection of antibodies against BCMA

US10851171B2 · kind B2 · utility

1Cited by

14References

4Claims

0Family size

Assignee

ENGMAB SARL · CH

Inventors

Minh Diem Vu · Wollerau, CH
Klaus Strein · Hemsbach, DE
Ekkehard Moessner · Kreuzlingen, CH
Ralf Hosse · Baar, CH
Oliver Ast · Bassersdorf, CH
Anne Freimoser-Grundschober · Bellinzona, CH
Marina BACAC · Schlieren, CH
Tanja Fauti · Zürich, CH
Christian Klein · Iffeldorf, DE
Pablo Umana · Wollerau, CH
Samuel Moser · Rotkreuz, CH

Key dates

Filing date	Apr 4, 2018
Grant date	Dec 1, 2020
Priority date	—
Expiry date	Dec 1, 2038

Classification

Technology area (CPC G)Physics
CPC primaryG01N2500/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-κB activation, BAFF-dependent NF-κB activation, and does not alter NF-κB activation without BAFF and APRIL is useful as a therapeutic agent.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.